Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

2 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Topotecan Post-Study Minimal Follow-up Report

- 21.08.19 - 1 Formular, 5 Itemgruppen, 19 Datenelemente, 1 Sprache
Itemgruppen: Administrative documentation, Follow-Up Report, Month, Patient Outcome, Cessation of life, Investigator Signature
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Post RT/Prior to Surgery

- 19.08.19 - 1 Formular, 4 Itemgruppen, 14 Datenelemente, 1 Sprache
Itemgruppen: Administrative documentation, Serious Adverse Event, 12 lead ECG, Experimental drug, Compliance behavior
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video